Literature DB >> 1316770

Quality of life during chemotherapy for small cell lung cancer. II. A longitudinal study of the EORTC Core Quality of Life Questionnaire and comparison with the Sickness Impact Profile.

B Bergman1, M Sullivan, S Sörenson.   

Abstract

Sixty-two patients with small cell lung cancer, 36-80 years of age, who were receiving chemotherapy during a maximum of one year, were consecutively included in a study of quality of life during treatment. An interim version (C-36) of the EORTC Core Quality of Life Questionnaire (QLQ) was applied for quality of life assessment prior to treatment and every third month during the treatment period. The assessments were related to clinical variables (performance status and tumour response), and compared with results from assessment with the Sickness Impact Profile (SIP). The QLQ was sensitive to differences in clinical status and responded to clinical change over time. In general, the pattern of correlations with SIP lends support to the construct validity of the QLQ. However, some questions arose from the comparison with SIP: QLQ emotional functioning did not change in concordance with SIP, and assessment of social functioning was not optimal prior to treatment. The questionnaire was well accepted by the patients. The EORTC QLQ C-36 constitutes a promising step in the development of a feasible standard instrument for quality of life assessment in cancer clinical trials.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1316770     DOI: 10.3109/02841869209088260

Source DB:  PubMed          Journal:  Acta Oncol        ISSN: 0284-186X            Impact factor:   4.089


  25 in total

1.  A follow-up study of the quality of life in cancer patients with different prognoses.

Authors:  G I Ringdal; K Ringdal
Journal:  Qual Life Res       Date:  2000-02       Impact factor: 4.147

2.  Quality-of-life assessment in small cell lung cancer.

Authors:  P Fayers
Journal:  Pharmacoeconomics       Date:  1992-09       Impact factor: 4.981

Review 3.  A review of the progress towards developing health-related quality-of-life instruments for international clinical studies and outcomes research.

Authors:  R T Anderson; N K Aaronson; M Bullinger; W L McBee
Journal:  Pharmacoeconomics       Date:  1996-10       Impact factor: 4.981

4.  Effect of neurological dysfunction on health-related quality of life in patients with high-grade glioma.

Authors:  D Osoba; N K Aaronson; M Muller; K Sneeuw; M A Hsu; W K Yung; M Brada; E Newlands
Journal:  J Neurooncol       Date:  1997-09       Impact factor: 4.130

Review 5.  Evaluation of quality of life for diverse patient populations.

Authors:  K R Yabroff; B P Linas; K Schulman
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

6.  Quality of life in terminal care--with special reference to age, gender and marital status.

Authors:  C Lundh Hagelin; Ake Seiger; C J Fürst
Journal:  Support Care Cancer       Date:  2005-09-28       Impact factor: 3.603

Review 7.  Critical review of the international assessments of health-related quality of life.

Authors:  R T Anderson; N K Aaronson; D Wilkin
Journal:  Qual Life Res       Date:  1993-12       Impact factor: 4.147

8.  Multilingual translation of the Functional Assessment of Cancer Therapy (FACT) quality of life measurement system.

Authors:  A E Bonomi; D F Cella; E A Hahn; K Bjordal; B Sperner-Unterweger; L Gangeri; B Bergman; J Willems-Groot; P Hanquet; R Zittoun
Journal:  Qual Life Res       Date:  1996-06       Impact factor: 4.147

9.  The impact of generalized malignant melanoma on quality of life evaluated by the EORTC questionnaire technique.

Authors:  V Sigurdardóttir; C Bolund; Y Brandberg; M Sullivan
Journal:  Qual Life Res       Date:  1993-06       Impact factor: 4.147

10.  The health-related quality of life and survival of small-cell lung cancer patients: results of a companion study to CALGB 9033.

Authors:  M J Naughton; J E Herndon; S A Shumaker; A A Miller; A B Kornblith; D Chao; J Holland
Journal:  Qual Life Res       Date:  2002-05       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.